SCHEMBL5062006

SCHEMBL5062006

CNc1ncc2cc(-c3cccc(NC(=O)Nc4cn(C(C)(C)C)nc4-c4cnsc4)c3)c(=O)n(C)c2n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.42
FGFR1 P11362 3/20 0.42
EGFR P00533 1/20 0.42
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
ABL1 P00519 4/20 0.40
PDGFRB P09619 2/20 0.40
PDGFRA P16234 2/20 0.40
MAPK14 Q16539 2/20 0.40
WEE1 P30291 4/20 0.39
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
STK26 Q9P289 1/20 0.39
STK24 Q9Y6E0 1/20 0.39
RIPK2 O43353 1/20 0.38
ACVR1 Q04771 1/20 0.38
FGFR4 P22455 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5052180 0.92 SRC (0.45) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5062384 0.91 FGFR1 (0.35) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054586 0.89 FGFR1 (0.44) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5056404 0.89 RAF1 (0.46) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5055093 0.89 RAF1 (0.46) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054950 0.89 FGFR1 (0.41) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054896 0.88 FGFR1 (0.42) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054961 0.88 SRC (0.44) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5055075 0.87 CYP1A2 (0.42) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5055132 0.87 SRC (0.41) SRCFGFR1EGFRRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 SRC 69/4885FGFR1 184/4885EGFR 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.